All In Biotech

Drug Trial Radar · NCT01529268

Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children

Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh)

Last checked: Nov 19, 2026Latest source record: Jun 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 169 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

169

Actual

Start

Jun 2012

Primary completion

Mar 2015

Study completion Sep 2015

Sponsor

Sponsor type
NIH
Collaborators
National Center for Advancing Translational Sciences (NCATS); National Cancer Institute (NCI); Raptor Pharmaceuticals
First posted
Feb 8, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CyNCh is a multi-center, placebo-controlled clinical trial of children ages 8 to 17 years with biopsy-confirmed moderate to severe nonalcoholic fatty liver disease (NAFLD). The primary objective is to evaluate whether 52 weeks of treatment with cysteamine bitartrate delayed-release capsules will result in improvement in liver disease severity.

Conditions

  • Nonalcoholic Fatty Liver Disease (NAFLD)

Interventions

  • DR cysteamine bitartrate capsuleDrug

    * 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline * 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline * 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline

  • DR cysteamine bitartrate placeboOther

    * 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline * 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline * 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in Nonalcoholic Fatty Liver Disease (NAFLD)Time frame: 52 weeks

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Diego

    San Diego, California

  • University of California, San Francisco

    San Francisco, California

  • Emory University

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago (NWU)

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • St. Louis University

    St Louis, Missouri

  • Columbia University

    New York, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Texas Children's Hospital

    Houston, Texas

  • University of Washington, Seattle Children's Hospital

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.